Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HIV test shortage

This article was originally published in The Gray Sheet

Executive Summary

Calypte Biomedical's April announcement of possible bankruptcy triggers CDC's May 10 warning of potential U.S. shortage of supplemental tests kits for confirmatory testing of HIV antibodies in specimens derived from patients or blood donors. Distributor bioMérieux has notified customers of a halt in Cambridge Biotech HIV-1 Western blot kit shipments. CDC and FDA have contacted other HIV test-makers, including BioRad Laboratories and OraSure, about ramping up kit production. Labs experiencing shortage should contact CDC at 404-639-4581...

You may also be interested in...

Supplemental HIV Testing Market Woes Force FDA To Consider Other Options

The financial instability of Calypte Biomedical over the past several months has increased FDA's interest in licensing alternative approaches for confirmatory HIV testing for blood banks, including nucleic acid testing

Teva Plans To Appeal EU Provigil Fine

Teva plans to begin appeal proceedings, the firm has told Generics Bulletin, after being fined €60.5m ($72m) by the European Commission over an historic “pay-for-delay” arrangement covering subsidiary firm Cephalon’s Provigil (modafinil).

Coronavirus Update: SK Bioscience, Biological E, DongWha And Celltrion Report Progress

SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts